Decision to Acquire 4.2 Billion Won Own Convertible Bonds Before Maturity, Potential Cancellation to Reduce Dilution


  • On May 22, 2026, Mezzion decided to acquire 4.2 billion won of its own convertible bonds (20% of total 21 billion won) before maturity through off-market purchase, upon agreement with bondholder.
  • The acquisition amount, including principal and interest, is 4.547 billion won, to be paid from internal funds on June 22, 2026.
  • Post-acquisition, remaining CB balance is 16.8 billion won; the board will decide on resale or cancellation.
  • The conversion price of 39,284 won is lower than the current stock price of 69,900 won, posing dilution risk; the buyback reduces potential dilution.
  • The acquired CBs, if converted, would issue 106,913 shares (0.35% of total shares); cancellation would eliminate this dilution effect.

KOSDAQ Filing Information


  • Filing: Report On Major Events (Decision On Acquisition Before Maturity Of Self-Convertible Bonds)
  • Company: Mezzion Pharma (140410)
  • Submission: Mezzion Pharma Co., Ltd.
  • Receipt: 05-22-2026